ストックスクリーナーアプリを入手
0.4882
2.36%
-0.0118
前日終値:
$0.50
開ける：
$0.52
24時間の取引高:
3.09M
Relative Volume:
0.71
時価総額：
$118.85M
収益：
$424.90K
当期純損益:
$-94.02M
株価収益率:
-0.1965
EPS:
-2.4842
ネットキャッシュフロー:
$-51.25M
1週間 パフォーマンス:
-18.48%
1か月 パフォーマンス:
-27.88%
6か月 パフォーマンス:
+80.55%
1年 パフォーマンス:
-63.57%
1日の値動き範囲:
$0.485
$0.5326
1週間の範囲:
$0.4379
$0.60
52週間の値動き範囲:
$0.1611
$2.5375
Outlook Therapeutics Inc Stock (OTLK) Company Profile
名前
Outlook Therapeutics Inc
セクター
電話
(609) 619-3990
住所
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.4882 | 118.85M | 424.90K | -94.02M | -51.25M | -2.4842 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-27 | アップグレード | BTIG Research | Neutral → Buy |
| 2026-05-18 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-08-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-02 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-02-15 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-27 | アップグレード | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-08-30 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | ダウングレード | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-07-13 | 開始されました | CapitalOne | Overweight |
| 2023-04-03 | 開始されました | Guggenheim | Buy |
| 2023-02-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-10-31 | 開始されました | BTIG Research | Buy |
| 2022-09-13 | 開始されました | Chardan Capital Markets | Buy |
| 2019-09-11 | 開始されました | Ladenburg Thalmann | Buy |
| 2019-05-16 | 開始されました | Oppenheimer | Outperform |
| 2019-04-22 | 開始されました | Ascendiant Capital Markets | Buy |
すべてを表示
Outlook Therapeutics Inc (OTLK) 最新ニュース
Two reported owners share voting power over a stake above 5% in Outlook Therapeutics (OTLK). - Stock Titan
Certain Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2026. - www.marketscreener.com
Outlook Therapeutics (Nasdaq:OTLK)Stock Analysis - Simply Wall Street
Outlook Therapeutics files CMS code application and Outlook Therapeutics stock trades at EUR 0.53 - AD HOC NEWS
Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Outlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.com - Investing.com Australia
Outlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.com - Investing.com Canada
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - The Manila Times
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - marketscreener.com
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - Yahoo Finance
OTLK Maintained by Ascendiant Capital -- Price Target Raised to $10.50 - GuruFocus
Outlook Therapeutics Inc. (OTLK) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Australia
Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Nigeria
Outlook Therapeutics CEO discusses LYTENAVA commercial launch - investing.com
Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Canada
Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com UK
Only one FDA-approved eye medicine of its type exists in the U.S. It’s LYTENAVA. - Stock Titan
AMZN: Amazon.com Inc Latest Stock Price, Analysis, News and Trading Ideas - stocktwits.com
People on the Move: Kevin Lundquist Named Chief Financial Officer of Outlook Therapeutics - BioBuzz
CFO at Outlook Therapeutics (NASDAQ: OTLK) gets 500,000 hiring options - Stock Titan
Outlook Therapeutics (NASDAQ: OTLK) CFO reports zero insider holdings - stocktitan.net
Outlook Therapeutics Announces CFO Transition and Board Change - The Globe and Mail
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ - Sahm
Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - VisionMonday.com
Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - visionmonday.com
Outlook Therapeutics appoints Kevin Lundquist as CFO as Lawrence Kenyon to depart - TradingView
Outlook Therapeutics Appoints Kevin Lundquist as Chief - GlobeNewswire
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference - marketscreener.com
Outlook Therapeutics hires a CFO for its only FDA-approved eye version of bevacizumab - stocktitan.net
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus - Stocktwits
Outlook Therapeutics (OTLK) investor held to 9.99% cap - Stock Titan
Outlook Therapeutics Inc (OTLK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Outlook Therapeutics, Inc. 2026: Revenue $8.7K, EPS ($0.15) — 10-Q Summary - TradingView
Outlook Therapeutics (OTLK) wins FDA exclusivity but holds limited cash - Stock Titan
Brookline Capital cuts Outlook Therapeutics stock price target on model update - Investing.com
Brookline Capital cuts Outlook Therapeutics stock price target on model update - Investing.com
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Outlook Therapeutics delays quarterly SEC filing - TipRanks
META_TITLE_QUOTE - Yahoo Finance
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Yahoo Finance
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Zacks Investment Research
Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - marketscreener.com
Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - moomoo.com
Outlook Therapeutics, Inc. SEC Filing (Aug 17, 2026) | OTLK NT 10-Q - Stock Titan
Outlook Therapeutics Posts Q3 Financials, Raises Funds for Lytenava Launch - visionmonday.com
Outlook Therapeutics Inc (OTLK) Stock News Today - TradingKey
MSN Money - MSN
Outlook Therapeutics Inc (OTLK) 財務データ
収益
当期純利益
現金流量
EPS
Outlook Therapeutics Inc (OTLK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sukhtian Faisal Ghiath | Director |
Jul 29 '26 |
Buy |
1.05 |
95,398 |
99,996 |
220,972 |
| Haddadin Yezan Munther | Director |
Jun 02 '26 |
Buy |
0.83 |
29,000 |
24,145 |
66,167 |
| Sukhtian Ghiath M. | Director |
May 28 '26 |
Buy |
0.59 |
8,539,709 |
5,000,000 |
22,092,068 |
| Sukhtian Faisal Ghiath | Director |
May 27 '26 |
Buy |
0.41 |
122,174 |
50,006 |
125,574 |
| Haddadin Yezan Munther | Director |
May 26 '26 |
Buy |
0.44 |
34,000 |
14,960 |
37,167 |
| THURMAN RANDY H | Director |
May 26 '26 |
Buy |
0.43 |
5,000 |
2,145 |
5,593 |
| HILZINGER KURT J | Director |
May 26 '26 |
Buy |
0.44 |
400,000 |
176,520 |
423,655 |
4.22%
大文字化:
|
ボリューム (24 時間):